DIAMMONIUM PHOSPHATE AND OTHER AMMONIUM SALTS AND THEIR USE IN PREVENTING CLOTTING

• US 20080075788A1
• Filed: 09/21/2007
• Published: 03/27/2008
• Est. Priority Date: 09/21/2006
• Status: Abandoned Application

• Current Assignee: Kyphon SARL (Medtronic Plc)
• Original Assignee: Kyphon SARL (Medtronic Plc)
• Inventors: Lee, Samuel, Louie, Stephanie, Wenz, Robert, Schwardt, Jeffrey D., Slater, Thomas A.
• Application Number:
  US11/859,291
• Publication Number:
  US 20080075788A1
• Time in Patent Office: Days
• US Class Current: 424/601
• CPC Class Codes: A61L 17/12 Homopolymers or copolymers of glycolic acid or lactic acid
• CPC Class Codes: A61L 24/001 Use of materials characterised by their function or physical properties
• CPC Class Codes: A61L 33/0041 characterised by the choice of an antithrombatic agent other than heparin heparinoïd A61L33/08; polypeptides A61L33/12

Abstract

The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.

Claims

1. A medical device selected from the group consisting of a) a medical device that comprises a polymer and an ammonium sulfate salt as part of the medical device, b) a medical device that comprises a powder component and a diammonium phosphate salt as part of the medical device and c) a medical device that comprises an ammonium salt that is part of the medical device.

2. The medical device of claim 1, wherein the medical device is a bone cement.

3. The medical device of claim 1, wherein the ammonium sulfate salt or the diammonium phosphate salt is used in excess and at least some of the excess diammonium phosphate salt or the ammonium sulfate salt leaches out during treatment of an animal.

4. The medical device of claim 1, wherein the medical device is a non-resorbable polymeric extruded medical device.

5. The medical device of claim 4, wherein the ammonium salt or the diammonium phosphate salt is concentrated primarily on the surface of the medical device.

6. The medical device of claim 2, further comprising one or more members selected from the group consisting of ammonium phosphate salts, ammonium chloride salts, ammonium bromide salts, ammonium iodide salts, dimethyl ammonium chloride salts, dimethyl ammonium methyl sulfate salts, dimethyl ammonium acetate salts, dipropyl ammonium phosphate salts, dimethyl ammonium nitrate salts, di(alkyl)dimethyl ammonium chloride salts, di(alkyl)dimethyl ammonium bromide salts, tetraalkyl ammonium salts, alkyl trimethyl ammonium salts, ammonium nitrate salts, ammonium thiocyanate salts, ammonium sulfaminate salts, dilauryl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, dimyristyl dimethyl ammonium chloride salts, dipalmityl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, stearamidopropyl PG-diammonium chloride phosphate salts, stearamidopropyl ethyldiammonium ethosulfate salts, stearamidopropyl dimethyl(myristyl acetate) ammonium chloride salts, stearamidopropyl dimethyl cetearyl ammonium tosylate salts, stearamidopropyl dimethyl ammonium chloride salts, stearamidopropyl dimethyl ammonium lactate salts, and mixtures thereof.

7. The medical device of claim 6, wherein the medical device further comprises one or more members selected from the group consisting of an ammonium salt of citrate, an ammonium salt of heparin, an ammonium salt of tartrate, an ammonium salt of oxalate, warfarin (Coumadin), heparin, Anisindione, Sintrom (Acenocoumarol), Warfilone, Miradon, 1,3-indanediones, antithrombin, protein C, and thrombomodulin.

8. A method comprising:

administering a composition comprising an ammonium salt to an individual to inhibit, delay or prevent blood clotting.

9. The method according to claim 8, wherein the ammonium salts are one or more members selected from the group consisting of diammonium phosphate salts, ammonium phosphate salts, ammonium chloride salts, ammonium bromide salts, ammonium iodide salts, ammonium sulfate salts, dimethyl ammonium chloride salts, dimethyl ammonium methyl sulfate salts, dimethyl ammonium acetate salts, dipropyl ammonium phosphate salts, dimethyl ammonium nitrate salts, di(alkyl)dimethyl ammonium chloride salts, di(alkyl)dimethyl ammonium bromide salts, tetraalkyl ammonium salts, alkyl trimethyl ammonium salts, ammonium nitrate salts, ammonium thiocyanate salts, ammonium sulfaminate salts, dilauryl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, dimyristyl dimethyl ammonium chloride salts, dipalmityl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, stearamidopropyl PG-diammonium chloride phosphate salts, stearamidopropyl ethyldiammonium ethosulfate salts, stearamidopropyl dimethyl(myristyl acetate) ammonium chloride salts, stearamidopropyl dimethyl cetearyl ammonium tosylate salts, stearamidopropyl dimethyl ammonium chloride salts, stearamidopropyl dimethyl ammonium lactate salts, and mixtures thereof.

10. The method of claim 9, wherein the ammonium salt is one or more members selected from the group consisting of diammonium phosphate salts, ammonium phosphate salts, ammonium chloride salts, ammonium bromide salts, ammonium iodide salts, and ammonium sulfate salts.

11. The method of claim 10, wherein the ammonium salt is a diammonium phosphate salt.

12. The method of claim 8, further comprising one or members from the group consisting of warfarin (Coumadin), heparin, Anisindione, Sintrom (Acenocoumarol), Warfilone, Miradon, 1,3-indanediones, antithrombin, protein C, and thrombomodulin.

13. The method of claim 12, wherein the pharmaceutical composition comprises heparin and heparin is present as an ammonium salt.

14. An anticoagulant comprising an ammonium salt wherein the ammonium salt is not an ammonium salt of citrate, an ammonium salt of heparin, an ammonium salt of tartrate, or an ammonium salt of oxalate.

15. The anticoagulant of claim 14, wherein the ammonium salt is one or more members selected from the group consisting of diammonium phosphate salts, ammonium phosphate salts, ammonium chloride salts, ammonium bromide salts, ammonium iodide salts, ammonium sulfate salts, dimethyl ammonium chloride salts, dimethyl ammonium methyl sulfate salts, dimethyl ammonium acetate salts, dipropyl ammonium phosphate salts, dimethyl ammonium nitrate salts, di(alkyl)dimethyl ammonium chloride salts, di(alkyl)dimethyl ammonium bromide salts, tetraalkyl ammonium salts, alkyl trimethyl ammonium salts, ammonium nitrate salts, ammonium thiocyanate salts, ammonium sulfaminate salts, dilauryl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, dimyristyl dimethyl ammonium chloride salts, dipalmityl dimethyl ammonium chloride salts, distearyl dimethyl ammonium chloride salts, stearamidopropyl PG-diammonium chloride phosphate salts, stearamidopropyl ethyldiammonium ethosulfate salts, stearamidopropyl dimethyl(myristyl acetate) ammonium chloride salts, stearamidopropyl dimethyl cetearyl ammonium tosylate salts, stearamidopropyl dimethyl ammonium chloride salts, stearamidopropyl dimethyl ammonium lactate salts, and mixtures thereof.

16. The anticoagulant of claim 14, wherein the anticoagulant is a bone cement.

17. The anticoagulant of claim 16, wherein the bone cement further comprises one or more antibiotics selected from the group consisting of gentamicin, gentamicin sulfate, erythromycin, tobramycin, vancomycin, cefazolin, oxacillin, cefotaxime, colistin, clindamycin, and fusidic acid.

18. The anticoagulant of claim 17, wherein the bone cement further comprises one or more anticancer agents and the one or more anticancer agents is selected from the group consisting of 6-mercaptopurine, methotrexate and cisplatin.

19. A pharmaceutical anticoagulant composition comprising an ammonium salt in connection with one or more of a pharmaceutically acceptable diluent, carrier, excipient, and/or other pharmaceutically acceptable salt.

20. The pharmaceutical composition of claim 19, further comprising one or more other anticoagulants wherein said one or more other anticoagulants is one or more members selected from the group consisting of an ammonium salt of citrate, an ammonium salt of heparin, an ammonium salt of tartrate, an ammonium salt of oxalate, warfarin (Coumadin), heparin, Anisindione, Sintrom (Acenocoumarol), Warfilone, Miradon, 1,3-indanediones, antithrombin, protein C, and thrombomodulin.

21. A medical product selected from the group consisting of a non-bioresorbable polymeric medical device, a bioresorbable polymeric medical device, a bioresorbable gel, hydrogel and an implant, wherein said medical product comprises an ammonium salt and wherein said medical product is designed to allow the ammonium salt to leach into a patient'"'"'s circulatory system.

22. The medical product of claim 21, wherein the medical product is a bioresorbable suture.

23. The medical product of claim 22, wherein the bioresorbable suture is made of a polylactic acid/polyglycic acid copolymer.

24. The medical product of claim 21, which is the non-bioresorbable polymeric medical device or the implant, wherein the non-bioresorbable polymeric medical device or the implant is extruded, molded or thermoformed.

25. The medical product of claim 24, wherein the non-bioresorbable polymeric implant is a catheter, a blood filter, a drip chamber, or a blood oxygenator.